Erythropoiesis-stimulating agents and antibody-mediated pure red-cell aplasia: here are we now and where do we go from here?
Open Access
- 1 February 2004
- journal article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 19 (2) , 288-293
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Pure red-cell aplasia due to anti-erythropoietin antibodiesNephrology Dialysis Transplantation, 2003
- Allergic Skin and Systemic Reactions in a Patient with Pure Red Cell Aplasia and Anti-Erythropoietin Antibodies Challenged with Different EpoetinsJournal of the American Society of Nephrology, 2002
- Bioequivalence and the immunogenicity of biopharmaceuticalsNature Reviews Drug Discovery, 2002
- Pure Red-Cell Aplasia and Recombinant ErythropoietinNew England Journal of Medicine, 2002
- Antibodies against rHuEPO: native and recombinantNephrology Dialysis Transplantation, 2002
- Inverse Relationship of Protein Concentration and AggregationPharmaceutical Research, 2002
- Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant ErythropoietinNew England Journal of Medicine, 2002
- Drug-Induced Autoimmune Red-Cell AplasiaNew England Journal of Medicine, 2002
- Antibodies against Recombinant Human Erythropoietin in a Patient with Erythropoietin-Resistant AnemiaNew England Journal of Medicine, 1996
- Autoantibodies against Erythropoietin in a Patient with Pure Red-Cell AplasiaNew England Journal of Medicine, 1996